Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility

References

• Siegel R, Jemal A. Cancer Facts & Figures 2012. American Cancer Society: Atlanta; 2012.
   Google Scholar
• Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009;107:1053–62.
   PubMed Web of Science ®Google Scholar
• (a) Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225–39. (b) Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4:601–5. (c) Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393–410.
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230–7.
   PubMed Web of Science ®Google Scholar
• Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510–14.
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang G-W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271–5.
   PubMed Web of Science ®Google Scholar
• Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005;2005:re12.
   PubMedGoogle Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–32.
   PubMed Web of Science ®Google Scholar
• Nicolaou KC, Pfefferkorn JA, Mitchell HJ, et al. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10‚000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J Am Chem Soc 2000;122:9954–67.
   Web of Science ®Google Scholar
• (a) Tan C, de Noronha RG, Devi NS, et al. Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg Med Chem Lett 2011;21:5528–32. (b) Narita T, Yin S, Gelin CF, et al. Identification of a novel small molecule HIF-1α translation inhibitor. Clin Cancer Res 2009;15:6128–36.
   PubMed Web of Science ®Google Scholar
• (a) Wang W, Ao L, Rayburn ER, et al. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One 2012;7:e44883. (b) Zhang Q, Kaluz S, Yang H, et al. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res 2012;18:6623–33.(c) Yin S, Kaluz S, Devi NS, et al. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1a interaction with co-factors p300/CBP. Clin Cancer Res 2012;18:6623–33.
   PubMed Web of Science ®Google Scholar
• Mooring SR, Jin H, Devi NS, et al. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J Med Chem 2011;54:8471–89.
   PubMed Web of Science ®Google Scholar
• (a) Ferguson J, De Los Santos Z, Devi N, et al. Examining the structure–activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway. Bioorg Med Chem Lett 2017;27:1731–6. (b) Prado S, Janin YL, Saint-Joanis B, et al. Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. Bioorg Med Chem 2007;15:2177–86.
   PubMed Web of Science ®Google Scholar
• (a) Sangster J. Octanal–water partition coefficients of small organic compounds. J Phys Chem Ref 1989;18:1111–227. (b) Acree WE, Grubbs LM, Abraham MH. Prediction of partition coefficients and permeability of drug metabolites in biological systems with Abraham model solute descriptors derived from measured solubilities and water-to-organic solvent partition coefficients. In: Acree B, ed. Toxicity and drug testing. InTech. Available from: http://www.intechopen.com/books/toxicity-and-drug-testing/prediction-of-partition-coefficients-and-permeability-of-drug-molecules-in-biological-systems-with-a
   Google Scholar
• Lipinksi CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3–25.
   Web of Science ®Google Scholar
• Bhal SK, Kassam K, Peirson IG, Pearl GM. The rule of five revisited: applying log D in place of log P in drug-likeness filters. Mol Pharm 2007;4:556–60.
   PubMed Web of Science ®Google Scholar
• Huuskonen J, Salo M, Taskinen J. Neural network modeling for estimation of the aqueous solubility of structurally related drugs. J Pharm Sci 1997;86:450.
   PubMed Web of Science ®Google Scholar
• Pecora R. Dynamic light scattering measurement of nanoparticles in liquids. J Nano Res 2000;2:123–31.
   Web of Science ®Google Scholar
• Berne BJ, Pecora R. Dynamic light scattering: with applications to chemistry, biology, and physics. North Chelmsford: Courier Corporation; 2000.
   Google Scholar